These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 38266552)
41. Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting. Lim JC; Cho EH; Kim JJ; Choi SM; Lee SY; Nam SS; Park UJ; Park SH Nucl Med Biol; 2015 Mar; 42(3):234-41. PubMed ID: 25498002 [TBL] [Abstract][Full Text] [Related]
42. Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma. Beaino W; Nedrow JR; Anderson CJ Mol Pharm; 2015 Jun; 12(6):1929-38. PubMed ID: 25919487 [TBL] [Abstract][Full Text] [Related]
44. Synthesis and preclinical evaluation of the 177Lu-DOTA-PSMA(inhibitor)-Lys3-bombesin heterodimer designed as a radiotheranostic probe for prostate cancer. Escudero-Castellanos A; Ocampo-García B; Ferro-Flores G; Santos-Cuevas C; Morales-Ávila E; Luna-Gutiérrez M; Isaac-Olivé K Nucl Med Commun; 2019 Mar; 40(3):278-286. PubMed ID: 30763290 [TBL] [Abstract][Full Text] [Related]
45. EDB-FN targeted probes for the surgical navigation, radionuclide imaging, and therapy of thyroid cancer. Li R; He H; Li X; Zheng X; Li Z; Zhang H; Ye J; Zhang W; Yu C; Feng G; Fan W Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2100-2113. PubMed ID: 36807768 [TBL] [Abstract][Full Text] [Related]
46. In vivo evaluation of PEGylated ⁶⁴Cu-liposomes with theranostic and radiotherapeutic potential using micro PET/CT. Petersen AL; Henriksen JR; Binderup T; Elema DR; Rasmussen PH; Hag AM; Kjær A; Andresen TL Eur J Nucl Med Mol Imaging; 2016 May; 43(5):941-952. PubMed ID: 26646780 [TBL] [Abstract][Full Text] [Related]
47. [ Lau J; Kwon D; Rousseau E; Zhang Z; Zeisler J; Uribe CF; Kuo HT; Zhang C; Lin KS; Bénard F Mol Pharm; 2019 Nov; 16(11):4688-4695. PubMed ID: 31545614 [TBL] [Abstract][Full Text] [Related]
48. Synthesis and Evaluation of Luna-Gutiérrez M; Cruz-Nova P; Jiménez-Mancilla N; Oros-Pantoja R; Lara-Almazán N; Santos-Cuevas C; Azorín-Vega E; Ocampo-García B; Ferro-Flores G Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569758 [TBL] [Abstract][Full Text] [Related]
49. Novel Radiolabeled TMTP1 for Long-Acting Hepatocellular Carcinoma Therapeutics. Yao L; Wen X; Guo W; Fang J; Zhang X; Guo Z; Huang J; Li Y Mol Pharm; 2022 Sep; 19(9):3178-3186. PubMed ID: 35972772 [TBL] [Abstract][Full Text] [Related]
50. A potencial theranostic agent for EGF-R expression tumors: (177)Lu-DOTA-nimotuzumab. Calzada V; Zhang X; Fernandez M; Diaz-Miqueli A; Iznaga-Escobar N; Deutscher SL; Balter H; Quinn TP; Cabral P Curr Radiopharm; 2012 Oct; 5(4):318-24. PubMed ID: 22280117 [TBL] [Abstract][Full Text] [Related]
52. α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts. Heskamp S; Hernandez R; Molkenboer-Kuenen JDM; Essler M; Bruchertseifer F; Morgenstern A; Steenbergen EJ; Cai W; Seidl C; McBride WJ; Goldenberg DM; Boerman OC J Nucl Med; 2017 Jun; 58(6):926-933. PubMed ID: 28232604 [TBL] [Abstract][Full Text] [Related]
53. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models. Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177 [TBL] [Abstract][Full Text] [Related]
54. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Zhang H; Schuhmacher J; Waser B; Wild D; Eisenhut M; Reubi JC; Maecke HR Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1198-208. PubMed ID: 17262215 [TBL] [Abstract][Full Text] [Related]
55. DOTA-tetrazine probes with modified linkers for tumor pretargeting. Läppchen T; Rossin R; van Mourik TR; Gruntz G; Hoeben FJM; Versteegen RM; Janssen HM; Lub J; Robillard MS Nucl Med Biol; 2017 Dec; 55():19-26. PubMed ID: 29028502 [TBL] [Abstract][Full Text] [Related]
56. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation. Koumarianou E; Mikołajczak R; Pawlak D; Zikos X; Bouziotis P; Garnuszek P; Karczmarczyk U; Maurin M; Archimandritis SC Nucl Med Biol; 2009 Aug; 36(6):591-603. PubMed ID: 19647165 [TBL] [Abstract][Full Text] [Related]
57. Development of [ Wen X; Xu P; Zeng X; Liu J; Du C; Zeng X; Cheng X; Wang X; Liang Y; Zhao T; Yang H; Li H; Meng L; Fang J; Liu H; Zhou Z; Zhang J; Zhang X; Guo Z; Chen X Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2846-2860. PubMed ID: 37097443 [TBL] [Abstract][Full Text] [Related]
58. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog Sauter AW; Mansi R; Hassiepen U; Muller L; Panigada T; Wiehr S; Wild AM; Geistlich S; Béhé M; Rottenburger C; Wild D; Fani M J Nucl Med; 2019 Mar; 60(3):393-399. PubMed ID: 30002107 [TBL] [Abstract][Full Text] [Related]
59. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. de Jong M; Breeman WA; Bernard BF; Bakker WH; Schaar M; van Gameren A; Bugaj JE; Erion J; Schmidt M; Srinivasan A; Krenning EP Int J Cancer; 2001 Jun; 92(5):628-33. PubMed ID: 11340564 [TBL] [Abstract][Full Text] [Related]
60. 3p-C-NETA: A versatile and effective chelator for development of Al Ahenkorah S; Murce E; Cawthorne C; Ketchemen JP; Deroose CM; Cardinaels T; Seimbille Y; Fonge H; Gsell W; Bormans G; Ooms M; Cleeren F Theranostics; 2022; 12(13):5971-5985. PubMed ID: 35966589 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]